Search
t-Butylhydroquinone
go.drugbank.com/drugs/DB07726ExperimentalCategories: Compounds used in a research, industrial, or household settingAI-850
go.drugbank.com/drugs/DB05842ExperimentalAI-850 is a Cremophor(R)-free formulation of paclitaxel, the active ingredient in Taxol(R), a product used to treat a variety of solid tumors.
Etizolam
go.drugbank.com/drugs/DB09166InvestigationalInitially introduced in 1983 in Japan as treatment for neurological conditions such as anxiety and sleep disorders, etizolam is marketed in Japan, Italy and India. … It is not approved for use by FDA in the US; however it remains unscheduled in several states and is legal for research purposes.
International brands: E1Tofisopam
go.drugbank.com/drugs/DB08811InvestigationalThe D-enantiomer ([dextofisopam]) is currently in phase II trials in the U.S. for the treatment of irritable bowel syndrome. … Although Tofisopam is not approved for sale in North America, it is approved for use in various countries worldwide, including parts of Europe.
Indium In-111 imciromab pentetate
go.drugbank.com/drugs/DB09339ApprovedWithdrawnIndium In-111 imciromab pentetate is a mouse monoclonal antibody labelled with the radioisotope Indium-111 which was used for cardiac imaging under the trade name Myoscint, but was withdrawn in 1993.
Synonyms: Indium In-111 myoscint, Myoscint indium In-111Oxantel
go.drugbank.com/drugs/DB13670InvestigationalOxantel is an anthelmintic drug that targets parasitic acetylcholine receptors.[A275093, A275098]
Icotinib
go.drugbank.com/drugs/DB11737InvestigationalIcotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc
Cefadroxil
go.drugbank.com/drugs/DB01140ApprovedInvestigationalVet approvedWithdrawnLong-acting, broad-spectrum, water-soluble, cephalexin derivative.
INS 316
go.drugbank.com/drugs/DB05390ExperimentalINS316 belongs to the family of drugs called nucleoside triphosphates.It is studied in the diagnosis of lung diseases, including lung cancer.
LX1031
go.drugbank.com/drugs/DB05199InvestigationalLX1031 is designed to act locally in the gastrointestinal tract by reducing the serotonin available for receptor activation, without affecting serotonin levels in the brain or its central nervous system … LX1031 is an orally-dosed drug candidate for irritable bowel syndrome and other gastrointestinal disorders.